Progress   –   Cancer-Med on the Move

   This page is to describe what we are doing and will do in the development of co-bodies for cancer diagnosis and treatment. The Research page is mostly about work by other people and deep levels of understanding. Here the subject is what Hybrid Antibody Technology and 21st Century have to do in the practical sense, as opposed to background corporate activities and expressed in everyday language.
    We have the central technology in place, but that is the starting point and not the end.
    Alternative technologies for making co-bodies must be explored, including the desirable option of administering the binding units separately so as to allow them to form the final co-body at the place where it is to act, which offers many advantages including better tissue penetration by smaller molecules.
    Once a co-body is bound to a cancer cell we need the tools to destroy that cell, and that is also a piece of unfinished business. Many assume that the best way must be to work by recruiting immune system cells to hit the cancer cell, but that is exactly what has caused difficulties with 'bispecifics' and other existing antibody systems. Attaching radioisotopes is another obvious choice which we reject out of hand because of their inability to deliver a knock-out blow where it is wanted and when it is needed. The timing of their radiation is by chance..
    There are hundreds or thousands of alternative cancer cell markers to be explored and then to make the corresponding antibodies or equivalent which are our raw materials. (From them, in turn, we construct millions of co-bodies each ‘made to measure’ for a particular cancer.) Just to collect and collate all the relevant scientific reports already in existence on this subject will require the work of a dozen people for six months.
    The next stage will be logistic   -   puttting togther stores and laboratory facilities, world-wide, to have raw materials ready when and where they are needed, test patients, and prepare co-bodies individually for each case ...
    .... and last of all will be training up the clinical personnel who will undertake treatment of individual patients